Research Article

Systematically In Silico Comparison of Unihormonal and Bihormonal Artificial Pancreas Systems

Xiaoteng Gao, Huangjiang Ning, and Youqing Wang

College of Information Science & Technology, Beijing University of Chemical Technology, Beijing 100029, China

Correspondence should be addressed to Youqing Wang; wang.youqing@ieee.org

Received 3 May 2013; Revised 17 August 2013; Accepted 26 August 2013

Academic Editor: Thierry Busso

Copyright © 2013 Xiaoteng Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Automated closed-loop control of blood glucose concentration is a daily challenge for type 1 diabetes mellitus, where insulin and glucagon are two critical hormones for glucose regulation. According to whether glucagon is included, all artificial pancreas (AP) systems can be divided into two types: unihormonal AP (infuse only insulin) and bihormonal AP (infuse both insulin and glucagon). Even though the bihormonal AP is widely considered a promising direction, related studies are very scarce due to this system’s short research history. More importantly, there are few studies to compare these two kinds of AP systems fairly and systematically. In this paper, two switching rules, P-type and PD-type, were proposed to design the logic of orchestrates switching between insulin and glucagon subsystems, where the delivery rates of both insulin and glucagon were designed by using IMC-PID method. These proposed algorithms have been compared with an optimal unihormonal system on virtual type 1 diabetic subjects. The in silico results demonstrate that the proposed bihormonal AP systems have outstanding superiorities in reducing the risk of hypoglycemia, smoothing the glucose level, and robustness with respect to insulin/glucagon sensitivity variations, compared with the optimal unihormonal AP system.

1. Introduction

According to a prediction produced by the International Diabetes Federation (IDF) in 2009, there will be approximately 285 million diabetic subjects by 2010 and about 439 million diabetic subjects by 2030 [1, 2]. Diabetes has become a big issue that seriously harms human health. To regulate the blood glucose level [3, 4], exogenous insulin infusion is one of our main choices. In the recent decades, there has been a great deal of interest in developing a closed loop system that embodies an automated insulin delivery system [5] for regulating blood glucose (BG) in type 1 diabetes. Unlike intravenous (IV) administration, however, the subcutaneous (SC) insulin infusion presents a control challenge owing to a finite absorption rate of insulin analogs. This challenge may induce excessive drug accumulation in the subcutaneous tissue and then even hypoglycemia (blood glucose lower than 70 mg/dL).

Short-term hypoglycemia may cause more damage to patients’ brain function and even cause death [6]. Therefore, minimizing or avoiding hypoglycemia is a daily challenge for diabetic patients. There are mainly three ways to rescue for hypoglycemia: mathematically minimizing the SC accumulation, suspending the insulin delivery (termed as prediction/suspending solution) [7, 8], and using glucagon as a counterregulatory agent in closed-loop system. The first method to handle hypoglycemia is to mathematically minimize the SC accumulation, for example, MPC [9–11]. We can design an objective function to optimally regulate the BG close to a target within the normoglycemic range and in the meantime to minimize the SC accumulation of insulin. Another strategy to avert hypoglycemia is a combination of glucose prediction [12] and insulin infusion suspending. The third solution is adding glucagon infusion [13].

Recently, El-Khatib et al. proposed a new scheme for glucose management [14]: dual subcutaneous infusion of insulin and glucagon, where a model prediction control (MPC) algorithm [15] was used to design the SC administration of insulin and a proportional-derivative control [16] was used to govern the glucagon infusion. Ward and his coworkers used the glucagon to prevent hypoglycemia in type 1 diabetes [17], where the fading memory proportional
Figure 1: The block diagram of simulation models. The simulation models for a virtual subject consist of a glucose subsystem, an insulin subsystem, a meal subsystem, and a glucagon subsystem.

Because IMC-PID is used to design the insulin and glucagon delivery rates in the proposed bihormonal AP systems, IMC-PID is also implemented in the uni-hormonal benchmark AP system. As introduced in the previous paragraph, adding prediction/suspending term can enhance the performance of the uni-hormonal AP system. There have been a number of reported studies for hypoglycemia prediction [7, 8]. To achieve the performance limitation of the uni-hormonal AP system with prediction/suspending term, the perfect prediction/suspending solution is included in the uni-hormonal benchmark AP system; hence, this system can be considered as an optimal uni-hormonal AP system. To the authors' best knowledge, this is the first work to compare the bihormonal AP system and the optimal uni-hormonal AP system fairly and systematically.

The rest of this paper is organized as follows. In Section 2, the simulation models were briefly introduced. In Section 3, the IMC-PID controller was described and two switching rules were also proposed for blood glucose management. As a comparative standard, the optimal prediction/suspending therapy was presented for minimizing hypoglycemia episodes. In Section 4, the simulation results demonstrated the feasibility and safety of BG regulation using the switching control theory; statistics results can be used to further compare these therapies quantitatively; the robustness of these therapies was compared with respect to meals size variations, insulin/glucagon sensitivity variations, and measurement noises. In Section 5, to test its robustness with respect to intersubject variability, the proposed therapies were tested on ten virtual subjects. Finally, Section 6 concludes this note.

2. Brief Introduction on Simulation Models

The dynamic model for a virtual subject [26] consists of a glucose subsystem, an insulin subsystem, a meal subsystem, and a glucagon subsystem. The detailed descriptions for the glucose and insulin subsystems were introduced in [27, 28], respectively; the meal subsystem was presented in the paper [29]. The glucagon subsystem was introduced in the paper [30].

The block diagram of the virtual subject is shown in Figure 1.
2.1. Glucose Subsystem. The glucose subsystem is described by the following four equations [27]:

\[
G(t) = \frac{Q_1(t)}{V_G},
\]

\[
\frac{dQ_1(t)}{dt} = -\left(\frac{F_{01}}{V_G G(t)} + x_1(t)\right) Q_1(t) + k_{12} Q_2(t) - F_R + U_G(t) + EGP_0 \left(1 - x_3(t)\right),
\]

\[
\frac{dQ_2(t)}{dt} = x_1(t) Q_1(t) + \left[k_{12} + x_2(t)\right] Q_2(t),
\]

\[
F_{01} = \begin{cases} \frac{F_{01}}{4.5} G(t) \geq 81 \text{ mg/dL}, \\ 0.003 \left( G - 9 \right) V_G G(t) \geq 162 \text{ mg/dL}, \end{cases}
\]

\[
F_R = \begin{cases} \frac{U_G(t)}{t_{\text{max,G}}}, & G(t) \geq 81 \text{ mg/dL}, \\ 0, & \text{otherwise}, \end{cases}
\]

where \(V_G\) is the distribution volume of the accessible compartment and \(Q_1\) and \(Q_2\) are the masses of glucose in the accessible and nonaccessible compartments, respectively. \(G(t)\) represents the glucose (measurable) concentration (mg/dL), \(k_{12}\) represents the transfer rate constant between \(Q_1\) and \(Q_2\), \(EGP_0\) is endogenous glucose production (EGP) extrapolated to the zero insulin concentration, \(F_{01}\) is the amount of noninsulin-dependent glucose corrected for the ambient glucose concentration, and \(F_R\) is the rate of renal glucose clearance above the glucose threshold of 162 (mg/dL). \(U_G(t)\) represents the gut absorption rate, \(t_{\text{max,G}}\) is the time of maximum appearance rate of glucose in the accessible glucose compartment, and \(D_G\) and \(A_G\) represent the amount of carbohydrates digested and carbohydrate bioavailability, respectively.

2.2. Insulin Subsystem. The insulin subsystem is described as follows [28]:

\[
\frac{dQ_{1a}}{dt} = k_u - k_{a1} Q_{1a} - LD_a,
\]

\[
\frac{dQ_{1b}}{dt} = (1 - k_u) Q_{1b} - k_{a2} Q_{1b} - LD_b,
\]

where \(Q_{1a}\) represents mass of insulin administered as continuous infusion, \(Q_{1b}\) is the mass of insulin given as a bolus, \(k\) represents the proportion of the total input flux passing through the slower, two compartment channel, \(k_{a1}\) and \(k_{a2}\) represent transfer rates, \(LD_a\) and \(LD_b\) are local degradation at the injection site for continuous infusion and bolus, \(Q_2\) and \(Q_1\) are the dose of in the nonaccessible subcutaneous compartments and the plasma compartment, respectively. \(k_{M,LD}\) represents the amount of insulin mass in which insulin degradation is equal to half of its maximal value for continuous infusion and bolus, and \(V_{MAX,LD}\) represents the saturation level describing Michaelis-Menten dynamics of insulin degradation for continuous infusion and bolus.

2.3. Meal Subsystem. This model describes glucose transit through the upper small intestine and stomach. Consider

\[
\begin{align*}
q_{sto1}(t) &= -k_{21} q_{sto1}(t) + D \delta(t), \\
q_{sto2}(t) &= -k_{empt} q_{sto2}(t) + k_{21} q_{sto1}(t), \\
q_{gut}(t) &= -k_{abs} q_{gut}(t) + k_{empt} q_{sto2}(t), \\
q_{sto}(t) &= q_{sto1}(t) + q_{sto2}(t),
\end{align*}
\]

where \(q_{sto}\) and \(q_{gut}\) present the amounts of glucose in the stomach and intestine, respectively; \(q_{sto1}\) and \(q_{sto2}\) are the solid and liquid phase, respectively; \(\delta(t)\) presents the impulse function; \(D\) presents the amount of ingested glucose; \(k_{21}\) and \(k_{empt}\) are the rates of grinding and gastric emptying, respectively; the \(k_{abs}\) present the rate constant of intestinal absorption.

2.4. Glucagon Subsystem. At the heart of the model is a two-compartment representation of glucagon kinetics [30]:

\[
\begin{align*}
\dot{h}_1 &= \frac{\left(u \cdot k_{gl} \cdot AG - h_1\right)}{\left(k_{g2} \cdot t_{\text{max,G}}\right)}, \\
\dot{h}_2 &= \frac{\left(h_1 - h_2\right)}{\left(k_{g2} \cdot t_{\text{max,G}}\right)}, \\
h &= h_1 + h_2,
\end{align*}
\]

where \(h\) is the glycogen conversion rate; \(t_{\text{max,G}}\) and \(AG\) present the time of maximum appearance rate of glucose and
glucagon bioavailability, respectively; $k_{g1}$ and $k_{g2}$ are transfer constants which affect the transfer speed. In Section 4, $k_{g1}$ and $k_{g2}$ are chosen as 1.50 and 0.63 for standard subject, respectively.

### 3. Controller Design

3.1. **IMC-PID Controller.** Due to its simple structure and excellent robustness, PID controller finds widespread implementation in the industrial process control. Therefore, a great deal of effort has been directed at designing the best turning parameters for different process models. Among various PID-tuning methods, internal model control (IMC) theory has greatly succeeded because of its simplicity, good robustness, and successful practical applications [33]. For short, this kind of PID is named IMC-PID. It is well known that different patients have various dynamics, so finding suitable turning parameters is a great challenge for clinical application. One promising candidate to handle this challenge is IMC-PID, because it has only one adjustable parameter $\lambda$.

The structure of the IMC controller is demonstrated in Figure 2, where $r$, $y$, and $d$ are the input, output, and load disturbances, respectively. $P(s)$ is the controlled subject, $M(s)$ is the subject's model, and $Q(s) = M^{-1}(s)F(s)$ ($M_-(s)$ is the minimum phase portion of $M(s)$ and $F(s)$ is a designed filter). In Figure 2, the part inside the dashed frame is a PID controller, $Q_c$, described by the following equation:

$$Q_c = \frac{M^{-1}(s)F(s)}{1 - M^{-1}(s)F(s)M(s)},$$

$$(5)$$

$$F(s) = \frac{1}{(\lambda s + 1)^n}. $$

From (5), one can determine the parameters of the PID controller. The order $n$ is decided by the order of the minimum phase portion ($M_-(s)$). The tradeoff between robust stability and output tracking performance can be balanced by the parameter $\lambda$. For smaller value of $\lambda$, the closed-loop system will have better output tracking performance but worse robustness, vice versa. The simulation results in Section 4 demonstrate that the proposed algorithm has great robustness.

3.2. **Perfect Predictive Algorithm and Insulin Pump Suspension.** According to the published studies, we have observed that the risk of “overcorrection hypoglycemia” is the greatest after a large amount of insulin. The simplest strategy to reduce hypoglycemia is to interrupt insulin delivery. It is clear that a key factor for suspending insulin infusion is having an accurate glucose predictor. Because virtual subjects were used in this study, the future glucose level can be exactly predicted using the subjects’ accurate model. Hence, the optimal time for the insulin infusion suspension can be obtained such that the lowest BG value is exactly higher than 70 mg/dL.

The dosing of insulin $u$ was determined by the following equation:

$$u = u_0 + u_{PID},$$

$$(6)$$

where $u_0$ is the basal insulin delivery rate [35, 36] and $u_{PID}$ is designed by using IMC-PID controller.

If a pending hypoglycemia event was alarmed by the perfect predictive algorithm, the insulin delivery rate $u$ will be forced to zero. Obviously, the above-mentioned algorithm can be considered the optimal uni-hormonal system.

3.3. **Switched Control System.** The switched control system in this study is a dynamic system that consists of two subsystems and a switching law [37] that orchestrates switching between these two subsystems [38]. The structure of the switched controller is shown in Figure 3.

Two kinds of switching rules [39] are proposed in this study as shown in the following equations.

(1) **P-type switching rule:** consider

$$\delta(t) = \begin{cases} 
1 & \text{if } e \geq k_{e1} \text{ mg/dL}, \\
0 & \text{if } e \leq -k_{e2} \text{ mg/dL},
\end{cases}$$

$$(7)$$

where $\delta(t) = 1$ indicates insulin subsystem active mode and $\delta(t) = 0$ indicates glucagon subsystem active mode; $e$ is the blood glucose tracking error; the positive constants $k_{e1}$ and $k_{e2}$ are thresholds for the switching controller.
Figure 4: Glucose management results of the standard subject under four algorithms, where the whole testing duration is 24 hours. (a) It shows all BG curves. (b) It shows the corresponding insulin infusion rate determined by switching controllers (P-type dual infusion therapy and PD-type dual infusion therapy, resp.). (c) It shows the corresponding glucagon infusion rate determined by switching controllers (P-type dual infusion therapy and PD-type dual infusion therapy, resp.).

(2) PD-type switching rule: consider
\[
\delta(t) = \begin{cases} 
1 & \text{if } ds \geq k_{s1}, \\
0 & \text{if } ds \leq -k_{s2},
\end{cases}
\]
\[
ds = e + k_s \frac{de}{dt},
\]

where \(k_{s1}\) and \(k_{s2}\) are thresholds; \(k_s > 0\) is a designed parameter. Substantially, \(ds\) can be considered a prediction of the future tracking error \(e\), where \(k_s\) is the prediction horizon.

4. In Silico Tests on Standard Virtual Subject

Based on metabolism model introduced in Section 2 and its suggested parameter settings in the literature [27–30], one virtual subject was built. For convenience, this subject was named standard subject. All simulation tests in Section 4 were finished on the standard subject. The test duration for each algorithm is 24 hours. Four kinds of closed-loop control methods were tested in each study: insulin-only therapy, prediction/suspending therapy, P-type dual infusion therapy, and PD-type dual infusion therapy. Total carbohydrate consumption consists of breakfast, lunch, and dinner (40, 60, and 85 g of carbohydrates, taking at 7:00, 12:00, and 18:00, resp.).

4.1. Nominal Case. All simulation tests consist of four cases. There is only insulin infusion determined by \(u = 0.42 + u_{PID}\) in the first case, where \(u_{PID}\) is designed by using IMC-PID controller. Figure 4(a) shows the closed-loop control performance of the insulin-only therapy, where \(\lambda = 0.40\) was used for the tuning parameter. However, the control result is still not good enough. Hypoglycemia occurred during the closed-loop test.

The second case is testing the glucose prediction and insulin suspension therapy. Through the combination of basal insulin and accurate suspending, tighter control of blood glucose can be achieved compared with the insulin-only therapy. As shown in Figure 4(a), the prediction/suspending therapy has superior capability to avoid hypoglycemia compared with the insulin-only therapy. The control algorithm can be described by

\[
u = \begin{cases} 
0.42 + u_{PID} & \text{no hypoglycemia alarm,} \\
0, & \text{have hypoglycemia alarm.}
\end{cases}
\]
Table 1: Statistical comparison for the insulin-only, prediction/suspending, P-type, and PD-type therapies on the standard subject, where BGI is the blood glucose index [34] and SD is the standard deviation of corresponding glucose curve.

| Therapies          | % of BG < 70 mg/dL | % of BG > 180 mg/dL | BGI  | SD (mg/dL) |
|--------------------|--------------------|---------------------|------|------------|
| Insulin-only therapy | 8                  | 0                   | 3.43 | 30.93      |
| Prediction/suspending | 0                  | 4                   | 3.13 | 33.60      |
| P-type therapy     | 0                  | 0                   | 0.70 | 16.28      |
| PD-type therapy    | 0                  | 0                   | 0.55 | 14.24      |

Figure 6: Comparison of four algorithms' robustness with respect to insulin sensitivity variations on the standard subject. (a) There are +20% variations on insulin sensitivity; (b) there are −20% variations on insulin sensitivity.

Figure 7: Comparison of two algorithms' robustness with respect to glucagon sensitivity variations on the standard subject. (a) There are +20% variations on glucagon sensitivity; (b) there are −20% variations on glucagon sensitivity.

The P-type switching controller was used in the third experiment. The dosing of insulin and glucagon was determined by IMC-PID controllers, respectively. The switching rule was demonstrated by the following equations:

\[ \delta(t) = \begin{cases} 
1 & \text{if } e > 5 \text{ mg/dL}, \\
0 & \text{if } e < -5 \text{ mg/dL}. 
\end{cases} \]

(10)

The fourth strategy is PD-type switching therapy. The dosing of insulin and glucagon was designed by IMC-PID controllers, respectively. The switching rule was described by

\[ \delta(t) = \begin{cases} 
1 & \text{if } ds > 15, \\
0 & \text{if } ds < -15. 
\end{cases} \]

(11)

4.2. Robustness Analysis. The robustness of a BG management therapy is a significant factor for clinical application. Some uncertainties of external conditions may lead to severe BG fluctuation. For example, the meal size and the sensitivities of insulin, and glucagon may change dramatically.

In the sequel, the robustness analysis consists of four components: studies on meal size variations, insulin sensitivity variations, glucagon sensitivity variations, and measurement
Table 2: Statistical results for experiments on the standard subject under the insulin-only, prediction/suspending, P-type, and PD-type therapies, when there are +50% or −50% variations on meal sizes.

| Meal size | Therapies          | % of BG <70 mg/dL | % of BG >180 mg/dL | BGI     | SD (mg/dL) |
|-----------|--------------------|-------------------|-------------------|---------|------------|
| +50%      | Insulin-only therapy | 11                | 0                 | 5.29    | 38.84      |
|           | Prediction/suspending | 9                 | 6                 | 4.64    | 41.39      |
|           | P-type therapy      | 0                 | 0                 | 1.00    | 20.64      |
|           | PD-type therapy     | 0                 | 0                 | 0.81    | 17.73      |
| −50%      | Insulin-only therapy | 0                 | 0                 | 1.95    | 21.98      |
|           | Prediction/suspending | 0                 | 0                 | 1.99    | 25.97      |
|           | P-type therapy      | 0                 | 0                 | 0.51    | 13.18      |
|           | PD-type therapy     | 0                 | 0                 | 0.30    | 9.74       |

In clinical practice, the inaccuracy of the continuous glucose monitoring system (CGMS) enormously affects the performance of the closed-loop control system. To simulate the measurement noises, white Gaussian noises with zero mean and $\sqrt{3}$ standard deviation have been added on the output. The closed-loop control results with measurement noises are shown in Figure 8. One can see that all blood glucose values can be kept in the safe range even though there are measurement noises, which demonstrates that the proposed method has good robustness with respect to measurement noises. In all five situations, PD-type therapy always has smaller BGI and SD values compared with P-type therapy. That is to say, PD-type therapy can control the glucose level more smoothly.

5. In Silico Tests on Group Subjects

5.1. Method to Create Group Virtual Subjects. In order to test whether the controller performed well for different subjects, the proposed strategy is evaluated on ten virtual subjects. Model parameters represent the high intersubject and temporal variation in insulin needs in type 1 diabetic subjects. Different combinations of free parameters in the metabolism model represent different virtual patients. These parameters are assumed to be log-normally distributed to ensure their non-negativity. Ten virtual subjects were generated using the joint distribution; that is, ten realizations of the log-transformed parameter vector were randomly extracted from the multivariate normal distribution characterizing intersubject variability. Finally, the parameters in these ten virtual subjects were obtained by using antitransformation [40]. In our opinion, these ten subjects could represent a wide range of type 1 diabetic population.
Figure 9: The blood glucose curves of ten virtual subjects under two proposed therapies: (a) P-type therapy; (b) PD-type therapy.

Table 3: Statistical results for experiments on the standard subject under the insulin-only, prediction/suspending, P-type, and PD-type therapies. There are two situations: +20% means that the insulin sensitivity is 20% higher than the nominal case; −20% means that the insulin sensitivity is 20% lower than the nominal case.

| Insulin sensitivity | Therapies          | % of BG <70 mg/dL | % of BG >180 mg/dL | BGI  | SD (mg/dL) |
|---------------------|--------------------|-------------------|--------------------|------|------------|
| +20%                | Insulin-only therapy | 16                | 0                  | 4.35 | 27.89      |
|                     | Prediction/suspending | 13               | 2                  | 3.97 | 31.23      |
|                     | P-type therapy      | 0                 | 0                  | 0.54 | 14.38      |
|                     | PD-type therapy     | 0                 | 0                  | 0.41 | 12.67      |
| −20%                | Insulin-only therapy | 6                 | 0                  | 3.31 | 35.64      |
|                     | Prediction/suspending | 0                | 6                  | 3.19 | 37.25      |
|                     | P-type therapy      | 0                 | 0                  | 1.08 | 20.26      |
|                     | PD-type therapy     | 0                 | 0                  | 0.79 | 15.51      |

Table 4: Statistical results for experiments on the standard subject under P-type and PD-type therapies. There are two situations: +20% means that the glucagon sensitivity is 20% higher than the nominal case; −20% means that the glucagon sensitivity is 20% lower than the nominal case.

| Glucagon sensitivity | Therapies | % of BG <70 mg/dL | % of BG >180 mg/dL | BGI  | SD (mg/dL) |
|----------------------|-----------|-------------------|--------------------|------|------------|
| +20%                 | P-type therapy | 0                | 0                  | 0.74 | 16.73      |
|                      | PD-type therapy | 0               | 0                  | 0.56 | 13.72      |
| −20%                 | P-type therapy | 0                | 0                  | 0.79 | 17.90      |
|                      | PD-type therapy | 0               | 0                  | 0.56 | 14.71      |

5.2. Simulation Results. All simulation results were demonstrated in BG response curves and control-variability grid analysis (CVGA) plots [41]. All of these ten subjects followed a two-day scenario. The BG response curves and CVGA plot in the second day (under the proposed therapies) are given in Figures 9 and 10, respectively. From Figure 9, one can see that all subjects have no hypoglycemic event and only one tiny hyperglycemic event under two therapies. In addition, 90% of subjects are within A-zone under both P-type and PD-type therapies as shown in Figure 10. These results indicate that these proposed closed-loop control algorithms can provide satisfactory BG control, and hence it is an excellent candidate for tight blood glucose control.

6. Conclusions

Two novel methods based on switched control theory, P-type and PD-type switching therapies, were proposed for
the bihormonal AP system. Systematic in silico tests demonstrate that these proposed bihormonal AP systems have superior glycemic control performance than the optimal uni-hormonal AP system. Using the bihormonal AP system, all glucose concentrations can be kept within the safe range. In addition, these proposed switching therapies have excellent robustness with respect to meal size variations, insulin/glucagon sensitivity variations, measurement noises, and intersubject variability. In terms of BGI and SD, the PD-type therapy is better than the P-type one. Hence, the bihormonal AP system based on switching control theory is a promising direction for BG management.

Acknowledgments

This work is supported by Doctoral Fund of Ministry of Education of China (20100010120001), the National Nature Science Foundation of China (61074081 & 61374099), the Beijing Nova Program (2011025), and the Fok Ying Tong Education Foundation (131060).

References

[1] L. Eiselein, H. J. Schwartz, and J. C. Rutledge, “The challenge of type 1 diabetes mellitus,” ILAR Journal, vol. 45, no. 3, pp. 231–236, 2004.
[2] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004.
[3] R. A. Harvey, Y. Wang, and B. Grosman, “Quest for the artificial pancreas combining technology with treatment,” IEEE Engineering in Medicine and Biology Magazine, vol. 29, pp. 53–62, 2010.
[4] S. O. Skrøvseth and F. Godtliebsen, “Scale space methods for analysis of type 2 diabetes patients’ blood glucose values,” Computational and Mathematical Methods in Medicine, vol. 2011, Article ID 672039, 7 pages, 2011.
[5] F. Campos-Cornejo, D. U. Campos-Delgado, D. Espinoza-Trejo et al., “An advisory protocol for rapid—and slow-acting insulin therapy based on a run-to-run methodology,” Diabetes Technology and Therapeutics, vol. 12, pp. 555–565, 2010.
[6] R. E. Teixeira and S. Malin, “The next generation of artificial pancreas control algorithms,” Journal of Diabetes Science and Technology, vol. 2, pp. 105–112, 2008.
[7] C. C. Palerm, J. P. Willis, J. Desemone, and B. W. Bequette, “Hypoglycemia prediction and detection using optimal estimation,” Diabetes Technology and Therapeutics, vol. 7, no. 1, pp. 3–14, 2005.
[8] B. Buckingham, E. Cobry, P. Clinton et al., “Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension,” Diabetes Technology and Therapeutics, vol. 11, no. 2, pp. 93–97, 2009.
[9] Y. Wang, H. Zisser, E. Dassau, L. Jovanović, and F. J. Doyle III, “Model predictive control with learning-type set-point: application to artificial pancreatic b-cell,” AICHe Journal, vol. 56, no. 6, pp. 1510–1518, 2010.
[10] R. S. Parker, F. J. Doyle III, and N. A. Peppas, “The intravenous route to blood glucose control,” IEEE Engineering in Medicine and Biology Magazine, vol. 20, pp. 65–73, 2001.
[11] Y. Wang, E. Dassau, and F. J. Doyle III, “Closed-loop control of artificial pancreatic beta-cell in type 1 diabetes mellitus using model predictive iterative learning control,” IEEE Transactions on Bio-Medical Engineering, vol. 57, no. 2, pp. 211–219, 2010.
[12] D. A. Finan, C. C. Palerm, F. J. Doyle III et al., “Effect of input excitation on the quality of empirical dynamic models for type 1 diabetes,” AICHe Journal, vol. 55, no. 5, pp. 1135–1146, 2009.
[13] S. J. Russell, F. H. El-Khatib, D. M. Nathan, and E. R. Damiano, “Efficacy determinants of subcutaneous microdose glucagon during closed-loop control,” Journal of Diabetes Science and Technology, vol. 4, no. 6, pp. 1288–1304, 2010.
[14] F. H. El-Khatib, J. Jiang, and E. R. Damiano, “A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine,” Journal of Diabetes Science and Technology, vol. 3, no. 4, pp. 789–803, 2009.
[15] R. S. Parker, F. J. Doyle III, and N. A. Peppas, “A model-based algorithm for blood glucose control in type I diabetic patients,” IEEE Transactions on Biomedical Engineering, vol. 46, no. 2, pp. 148–157, 1999.
[16] G. Marchetti, M. Barolo, L. Jovanović, H. Zisser, and D. E. Seborg, “An improved PID switching control strategy for type 1 diabetes,” IEEE Transactions on Biomedical Engineering, vol. 55, no. 3, pp. 857–865, 2008.
[17] W. K. Ward, J. Engle, H. M. Duman, C. P. Bergstrom, S. F. Kim, and I. F. Federiuk, “The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes,” IEEE Sensors Journal, vol. 8, no. 1, pp. 89–96, 2008.
[18] J. R. Castle, J. M. Engle, J. El Youssef et al., “Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes,” Diabetes Care, vol. 33, no. 6, pp. 1282–1287, 2010.
[19] F. H. El-khatib, S. J. Russell, D. M. Nathan, R. G. Sutherlin, and E. R. Damiano, “A bihormonal closed-loop artificial pancreas for type 1 diabetes,” Science Translational Medicine, vol. 2, no. 27, article 27ra27, 2010.
[20] F. H. El-Khatib, J. Jiang, and E. R. Damiano, “Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine,” Journal of Diabetes Science and Technology, vol. 1, pp. 181–192, 2007.
Z. Guisheng, I. Matsune, J. Imae, and T. Kobayashi, "A note on multiple Lyapunov functions and stability condition for switched and hybrid systems," in *Proceeding of the 16th IEEE International Conference on Control Applications (CCA ’07)*, pp. 226–231, Singapore, October 2007.

D. Liberzon and A. S. Morse, "Basic problems in stability and design of switched systems," *IEEE Control Systems Magazine*, vol. 19, no. 5, pp. 59–70, 1999.

Y. Wang, T. Liu, and Z. Zhao, "Advanced PI control with simple learning set-point design: application on batch processes and robust stability analysis," *Chemical Engineering Science*, vol. 71, pp. 153–165, 2012.

K. Tanaka, T. Hori, and H. O. Wang, "A dual design problem via multiple Lyapunov functions," in *Proceedings of the 10th IEEE International Conference on Fuzzy Systems*, pp. 388–391, Melbourne, Australia, December 2001.

E. Dassau, E. Atlas, and M. Phillip, "Closing the loop," *International Journal of Clinical Practice*, vol. 65, pp. 20–25, 2011.

B. P. Kovatchev, M. Breton, C. Dalla Man, and C. Cobelli, "In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes," *Journal of Diabetes Science and Technology*, vol. 3, pp. 44–55, 2009.

R. Hovorka, V. Canonico, L. J. Chassin et al., "Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes," *Physiological Measurement*, vol. 25, no. 4, pp. 905–920, 2004.

M. E. Wilinska, L. J. Chassin, H. C. Schaller, L. Schaupp, T. R. Pieber, and R. Hovorka, "Insulin kinetics in type-1 diabetes: continuous and bolus delivery of rapid acting insulin," *IEEE Transactions on Biomedical Engineering*, vol. 52, no. 1, pp. 3–12, 2005.

C. Dalla Man, M. Camilleri, and C. Cobelli, "A system model of oral glucose absorption: validation on gold standard data," *IEEE Transactions on Biomedical Engineering*, vol. 53, pp. 2472–2478, 2006.

X. Gao and Y. Wang, "Closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon based on switching PID controller," in *Proceedings of the 10th World Congress on Intelligent Control and Automation (WCICA ’12)*, pp. 5023–5029, Beijing, China, 2012.

C. Dalla Man, R. A. Rizza, and C. Cobelli, "Meal simulation model of the glucose-insulin system," *IEEE Transactions on Biomedical Engineering*, vol. 54, no. 10, pp. 1740–1749, 2007.

C. Dalla Man, D. M. Raimondo, R. A. Rizza, and C. Cobelli, "GIM, simulation software of meal glucose-insulin model," *Journal of Diabetes Science and Technology*, vol. 1, pp. 323–330, 2007.

M.-D. Hou, Z.-C. Zhao, J.-G. Zhang, and J. Tian, "An IMC-PID control method with set-point weight," in *Proceedings of the International Conference on Computational Intelligence and Security (CIS ’09)*, pp. 45–49, Beijing, China, December 2009.

B. P. Kovatchev, D. J. Cox, L. A. Gonder-Frederick, and W. Clarke, "Symmetrization of the blood glucose measurement scale and its applications," *Diabetes Care*, vol. 20, no. 11, pp. 1655–1658, 1997.

J. Bondia, E. Dassau, H. Zisser et al., "Coordinated basal-bolus infusion for tighter postprandial glucose control in insulin pump therapy," *Journal of Diabetes Science and Technology*, vol. 3, no. 1, pp. 89–97, 2009.